Perkins Capital Management Inc. Sells 146,000 Shares of Apyx Medical Corporation $APYX

Perkins Capital Management Inc. decreased its position in shares of Apyx Medical Corporation (NASDAQ:APYX) by 64.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 81,000 shares of the company’s stock after selling 146,000 shares during the quarter. Perkins Capital Management Inc. owned 0.21% of Apyx Medical worth $173,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Fisher Asset Management LLC bought a new position in Apyx Medical in the 2nd quarter valued at approximately $34,000. Osaic Holdings Inc. bought a new stake in shares of Apyx Medical in the 2nd quarter worth $50,000. Salem Investment Counselors Inc. purchased a new position in shares of Apyx Medical in the third quarter worth $97,000. Kingsview Wealth Management LLC lifted its holdings in shares of Apyx Medical by 9.4% during the second quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock valued at $431,000 after purchasing an additional 16,502 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Apyx Medical by 10.0% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 986,503 shares of the company’s stock valued at $2,111,000 after purchasing an additional 89,767 shares in the last quarter. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Price Performance

NASDAQ APYX opened at $3.97 on Monday. The company has a 50-day moving average price of $3.80 and a 200-day moving average price of $2.94. Apyx Medical Corporation has a 52 week low of $0.76 and a 52 week high of $4.44. The company has a quick ratio of 3.61, a current ratio of 4.44 and a debt-to-equity ratio of 5.69. The firm has a market capitalization of $151.81 million, a P/E ratio of -11.03 and a beta of 1.53.

Apyx Medical (NASDAQ:APYX) last announced its earnings results on Thursday, November 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Apyx Medical had a negative net margin of 30.35% and a negative return on equity of 151.01%. The company had revenue of $12.88 million during the quarter, compared to analyst estimates of $12.00 million. Equities research analysts anticipate that Apyx Medical Corporation will post -0.68 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research note on Wednesday, December 17th. Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. Citizens Jmp upgraded shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a report on Wednesday, November 12th. Finally, Roth Mkm started coverage on shares of Apyx Medical in a research note on Monday, December 15th. They set a “buy” rating and a $6.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.